Why Revolution Medicines, Inc. (RVMD) stock moved
Revolution Medicines, Inc. (RVMD) shares climbed 7.3% to $195.46 as of October 20, 2026, a significant gain from the prior close of $182.15. BestStocks flagged the session as a major change for RVMD. Below, we break down what changed for RVMD, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
RVMD climbed 7.3% to $195.46
Revolution Medicines announced enrollment has begun in its Phase 3 RASolve 308 trial testing zoldonrasib combined with pembrolizumab and chemotherapy for first-line metastatic RAS G12D non-squamous non-small cell lung cancer (Globe Newswire). RVMD rose 6.34% to $193.69 intraday. Volume data not yet reliable 45 minutes into session. RVMD earnings on 2026-11-04 (date not yet confirmed) and interim or topline data from the RASolve 308 trial.
What it means for Revolution Medicines, Inc. investors
For Revolution Medicines, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Strong 7.3% price move on light volume; Positive price momentum. Weighing against that: Revolution Medicines declined 3.11% to $187.92 as the stock continues a pullback following newly released FDA review documents for its pancreatic cancer drug Rasonque (daraxonrasib) that raised questions about varying response patterns across specific KRAS mutation subtypes, according to Yahoo Finance; Revolution Medicines shares fell 4.18% to $196.30, driven by a combination of profit-taking following the FDA's recent Breakthrough Therapy Designation for pancreatic cancer drug Rasonque, plus insider selling pressure. Wall Street's consensus price target sits at $253.47, implying +29.7% upside from $195.46. BestStocks rates the overall signal quality low (55/100). With earnings roughly 15 days out, the next report is the most likely near-term test of the move.
RVMD price reaction
RVMD last traded at $195.46, up $13.31 (+7.31%) from the previous close of $182.15. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $177.96 and $207.68, and it currently sits about 59% of the way up that band.
Bullish and bearish analyst opinions on Revolution Medicines, Inc. (RVMD)
The consensus analyst price target on Revolution Medicines, Inc. (RVMD) is $253.47, 29.7% above the recent $195.46. Over the past 90 days analysts logged 0 upgrades, 24 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RVMD line up.
The bullish case
- Wall Street's consensus price target of $253.47 implies +29.7% upside from $195.46.
- The Street's most bullish target is $320.00 (+63.7%).
- Strong 7.3% price move on light volume.
- Positive price momentum.
- Revolution Medicines, Inc. (RVMD) moved +5.79% from $182.08 to $192.62 on 2026-06-29, reaching a new 30-day high.
The bearish case
- The most bearish analyst target is $179.00 (-8.4%).
- Revolution Medicines declined 3.11% to $187.92 as the stock continues a pullback following newly released FDA review documents for its pancreatic cancer drug Rasonque (daraxonrasib) that raised questions about varying response patterns across specific KRAS mutation subtypes, according to Yahoo Finance.
- Revolution Medicines shares fell 4.18% to $196.30, driven by a combination of profit-taking following the FDA's recent Breakthrough Therapy Designation for pancreatic cancer drug Rasonque, plus insider selling pressure.
- RVMD fell 3.04% to $186.76 on below-average volume (0.47x expected at 90 minutes into the session).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RVMD
In-depth RVMD event analyses
Frequently asked questions about RVMD
Why did Revolution Medicines, Inc. (RVMD) stock move?
RVMD climbed 7.3% to $195.46. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did RVMD stock rise?
RVMD gained 7.31% ($13.31) versus the prior close of $182.15, last trading at $195.46 on 0.6× average volume.
When is Revolution Medicines, Inc.'s next earnings date?
RVMD's next earnings report is estimated for 2026-11-04 — about 15 days away.
What is the analyst price target for RVMD?
The consensus analyst price target for RVMD is $253.47, about 29.7% above the current $195.46. Over the past 90 days, analysts recorded 0 upgrades, 24 maintains, and 0 downgrades.
How BestStocks tracks RVMD
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared RVMD-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for RVMD, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.